Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD3XMG)

• Drug Name: AFTVac Drug Info
• Synonyms: Autologous fixed tumor vaccine (AFTVac) therapy; Autologous vaccine (cancer), Cell-Medicine; GM-CSF agonist/IL-2 agonist containing-vaccine; Fixed autologous tumor derivatives + microparticles encapsulating GM-CSF and IL-2, Cell-Medicine

Indication

Disease Entry	ICD 11	Status	REF
Glioblastoma multiforme	2A00.0	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMD3XMG

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin 2 receptor beta (IL2RB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKTR 214	DM376WT	Melanoma	2C30	Phase 3	[2]
NKTR-214	DMACYW6	Melanoma	2C30	Phase 3	[3]
Leukocyte interleukin	DM2B0TJ	Head and neck cancer	2D42	Phase 1	[4]
DAB-486-IL-2	DM54T8J	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting GMCSFR-alpha (CSF2RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sargramostim	DMY0M8J	Bone marrow transplantation	QB63.6	Approved	[6]
B-cell lymphoma vaccine	DMBRFUQ	Follicular lymphoma	2A80	Preregistration	[7]
Pixykine	DMCA6BW	Human immunodeficiency virus infection	1C62	Phase 3	[8]
Molgramostim	DM2TNJ1	Autoimmune pulmonary alveolar proteinosis	CB04.31	Phase 3	[9]
Mavrilimumab	DMMVFRC	Rheumatoid arthritis	FA20	Phase 2	[10]
GM-CSF cancer vaccine	DML6PO5	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
Leukemia cancer vaccine	DMIFGLY	Acute myeloid leukaemia	2A60	Phase 2	[11]
Myeloma cancer vaccine	DMO1XUK	Multiple myeloma	2A83	Phase 2	[11]
MOR-103	DMXVIQN	Multiple sclerosis	8A40	Phase 1/2	[12]
KH-901	DMR14VE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GMCSFR-alpha (CSF2RA)	TT6MP2Z	CSF2R_HUMAN	Not Available	[1]
Interleukin 2 receptor beta (IL2RB)	TT9721Y	IL2RB_HUMAN	Not Available	[1]

References

• [1] Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.
• [4] Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64.
• [5] Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur J Immunol. 1992 Mar;22(3):697-702.
• [6] Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9.
• [7] Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2.
• [8] Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7.
• [9] Clinical pipeline report, company report or official report of gensci-china.
• [10] Clinical pipeline report, company report or official report of MedImmune (2011).
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
• [12] MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64.
• [13] Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90.